STRATA Skin Sciences affirms patent portfolio for XTRAC laser therapies, expands CPT codes.

• STRATA Skin Sciences affirms its patent portfolio for XTRAC excimer laser combination therapies. • IP and market exclusivity for JAK inhibitor, systemic and biologic drugs. • Expanded CPT codes for inflammatory and autoimmune skin conditions to be included in CMS fee schedule by 2026. • Growing market opportunities through new indications and technology investments.

STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company specializing in innovative dermatologic treatments, has announced significant advancements in its intellectual property (IP) portfolio. The company has affirmed its strong patent position for combination therapies using its XTRAC excimer laser with JAK inhibitors, systemic, and biologic drugs [1].

STRATA's patent portfolio includes three key granted patents:
1. A worldwide method of use patent (WO2021053673A1) for localized treatment of skin conditions using UVB light (Excimer laser) and systemic drugs.
2. A U.S. method of use patent (US20220305282A1) specifying the use of Excimer laser and JAK inhibitors.
3. Another U.S. method of use patent (US20220296919A1) for the use of Excimer laser in combination with biological drugs for treating skin conditions.

These patents protect the combined use of the company's technology with various therapeutic agents, positioning STRATA at the forefront of integrative dermatologic treatment. The patents address the limitations of Excimer laser therapy by combining phototherapy with systemic treatments, enhancing treatment response, and improving safety [1].

STRATA is working with the Centers for Medicare and Medicaid Services (CMS) to implement expanded Current Procedural Terminology (CPT) codes that would cover all inflammatory and autoimmune skin conditions, potentially tripling their addressable market by January 2026. This expansion includes conditions like vitiligo, atopic dermatitis, and alopecia areata, beyond their current psoriasis treatment. The recent American Medical Association CPT code expansion represents a major financial catalyst, with updated codes extending reimbursement eligibility beyond psoriasis to include these conditions [1].

The company is also engaged in defensive litigation with LaserOptek, expecting significant damages and injunctive relief, which could further strengthen its market position. STRATA's patent portfolio secures exclusive rights for combination therapies, creating significant market exclusivity and competitive barriers as the company expands into new dermatological indications [2].

These strategic moves underscore STRATA's commitment to leveraging its technology for expanded clinical applications and demonstrating its dedication to patient care, good partnership, and shareholder value. By securing temporary CMS codes and protecting its combination therapy methods, STRATA positions itself to capture significant market share in the growing dermatological treatment sector [1].

References:
[1] https://www.globenewswire.com/news-release/2025/09/02/3142649/23161/en/STRATA-Skin-Sciences-IP-Portfolio-Holds-Exclusivity-in-Combination-Therapies-of-Its-XTRAC-Excimer-Laser-with-JAK-Inhibitors-Systemic-and-Biologic-Drugs-Bolstering-Expansion-into-Ne.html
[2] https://www.stocktitan.net/news/SSKN/strata-skin-sciences-ip-portfolio-holds-exclusivity-in-combination-47evzoz3s283.html